Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Georg Zerban

Rainer Hamm

Arndt Hausherr

Gunter Koch

Heinz-Peter Schmitt

Kerstin Schlarb

Bjoern Weyell

Ulrich Scholz

Oliver Meyer

Ingo Heddesheimer

Christian Filser

Wolfgang Dersch

Bjoem Weyell

Björn Weyell

The invention relates to a process for preparing the compound of formula 1 a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.

Method for producing an intermediate product of dabigatran etexilate

The invention relates to a process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterized in that

Process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof

The invention relates to a process for preparing a salt of an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterised in that

Process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides

A process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)benzamidine, the process comprising:

1,2,4-oxadiazol-5-one-4-(benzimidazolylmethylamino)benzamidine compounds

Process for the preparation of 4-(benzimidazolymethylamino) benzamidines

The invention provides a process for making compounds of the general formula I: wherein R, R, R, Rand Q are defined as in claim. The compounds of the general formula I are effective inhibitors of HIV reverse transcriptase.

Process for making a non-nucleoside HIV-1 reverse transcriptase inhibitor

Growing community of inventors

Ingelheim, Germany

Georg Zerban